Literature DB >> 23192584

Disturbance of consciousness and involuntary movements caused by pregabalin.

Taro Shimizu1, Tsuneyasu Yoshida, Koichi Kitamura, Osamu Hamada.   

Abstract

A 91-year-old man with chronic low-back pain presented with 1-day history of disturbance of consciousness and myoclonus of all of his extremities and face. Laboratory examinations revealed no abnormalities. Administration of benzodiazepine for the myoclonus resulted in immediate and complete disappearance of the symptoms. He recently started taking pregabalin (Lyrica capsules) which was prescribed for low-back pain 3 days ago. The day following admission, he discontinued pregabalin. He did not experience recurrence of his symptoms any more. We concluded that the neurological symptoms he experienced were possibly due to pregabalin.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23192584      PMCID: PMC4544218          DOI: 10.1136/bcr-2012-007559

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  19 in total

1.  Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro.

Authors:  Mark O Cunningham; Gavin L Woodhall; Sarah E Thompson; David J Dooley; Roland S G Jones
Journal:  Eur J Neurosci       Date:  2004-09       Impact factor: 3.386

2.  Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex.

Authors:  Klaus Fink; David J Dooley; Wolfgang P Meder; Nirmala Suman-Chauhan; Sandra Duffy; Hans Clusmann; Manfred Göthert
Journal:  Neuropharmacology       Date:  2002-02       Impact factor: 5.250

3.  Gabapentin is not a GABAB receptor agonist.

Authors:  C Lanneau; A Green; W D Hirst; A Wise; J T Brown; E Donnier; K J Charles; M Wood; C H Davies; M N Pangalos
Journal:  Neuropharmacology       Date:  2001-12       Impact factor: 5.250

Review 4.  Algorithm for neuropathic pain treatment: an evidence based proposal.

Authors:  N B Finnerup; M Otto; H J McQuay; T S Jensen; S H Sindrup
Journal:  Pain       Date:  2005-10-06       Impact factor: 6.961

5.  Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV).

Authors:  M Bialer; S I Johannessen; H J Kupferberg; R H Levy; P Loiseau; E Perucca
Journal:  Epilepsy Res       Date:  1999-03       Impact factor: 3.045

6.  Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial.

Authors:  R H Dworkin; A E Corbin; J P Young; U Sharma; L LaMoreaux; H Bockbrader; E A Garofalo; R M Poole
Journal:  Neurology       Date:  2003-04-22       Impact factor: 9.910

7.  Pregabalin for the discontinuation of long-term benzodiazepines use: an assessment of its effectiveness in daily clinical practice.

Authors:  J Bobes; G Rubio; A Terán; G Cervera; V López-Gómez; I Vilardaga; M Pérez
Journal:  Eur Psychiatry       Date:  2011-02-21       Impact factor: 5.361

8.  Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial.

Authors:  Rainer Sabatowski; Rafael Gálvez; David A Cherry; Florence Jacquot; Emmanuelle Vincent; Pascal Maisonobe; Mark Versavel
Journal:  Pain       Date:  2004-05       Impact factor: 6.961

9.  Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations.

Authors:  Laura D Errante; Ognen A C Petroff
Journal:  Seizure       Date:  2003-07       Impact factor: 3.184

10.  Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial.

Authors:  Robert van Seventer; Hilary A Feister; James P Young; Malcolm Stoker; Mark Versavel; Laurence Rigaudy
Journal:  Curr Med Res Opin       Date:  2006-02       Impact factor: 2.580

View more
  1 in total

1.  Delayed onset of rotatory self-motion perception, dysdiadochokinesia and disturbed eye pursuit caused by low-dose pregabalin.

Authors:  Patrice Hounnou; Keyvan Nicoucar
Journal:  BMJ Case Rep       Date:  2014-04-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.